New imaging method for vision loss from USH2A gene changes
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new imaging technique to better understand and monitor a type of inherited vision loss caused by changes in the USH2A gene. It may help improve diagnosis and future treatment planning for people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have a confirmed genetic test showing the USH2A gene change related to your vision loss.
- You have had genetic testing to confirm the specific gene change.
- You do not have other active eye diseases (like inflammation, infection, or degeneration).
- You have not had eye surgery in the last six months.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This 24-month study tests an experimental medication, NPI-001, to see if it can slow or prevent further vision loss in people with Usher syndrome. Usher syndrome affects hearing and vision, and this trial focuses on protecting the light-sensing cells in the retina.
This study tests a 24-month treatment with NPI-001, an oral medication, to see if it can slow the loss of light-sensing cells in the retina for people with retinitis pigmentosa tied to Usher syndrome. It aims to preserve remaining vision and delay further damage.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
Hear when a new USH2A Variant Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.